Project Details
Description
PROJECT NARRATIVE
Skeletal muscle has a remarkable capacity for repair in response to mild trauma, however, the amount of damage
associated with volumetric muscle loss (VML) overwhelms the regenerative process, ultimately resulting in scar
tissue deposition and compromised functionality. Although treatment options are very limited for VML, the use
of bioscaffolds composed of extracellular matrix (ECM) has shown promise in preclinical studies and a 13 patient
human cohort study. The proposed studies will define the functions of a newly discovered component of the
ECM, interleukin-33 (IL-33), in remodeling after skeletal muscle injury. Apart from the potential use of ECM-
associated IL-33 as prognostic biomarker for tissue regenerative capacity, this study will determine if ECM
associated IL-33 can be harnessed for tissue engineering/regenerative medicine applications.
Status | Finished |
---|---|
Effective start/end date | 1/04/18 → 31/01/23 |
Funding
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $439,985.00
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $517,163.00
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $543,891.00
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $446,854.00
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: $534,763.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.